Clinical References

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Prescribing Information Patient Information Return to singulair.com

References

  1. Wang D, Clement P, Smitz J, De Waele M, Derde M-P. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol. 1995;106:278–285.
  2. Dykewicz MS, Fineman S, Skoner DP, et al; for Joint Council on Allergy, Asthma and Immunology. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1998;81:478–518.
  3. Bousquet J, van Cauwenberge P, Khaltaev N, et al; and ARIA Workshop Group. Co-morbidity and complications. J Allergy Clin Immunol. 2001;108(suppl):S198–S207.
  4. Philip G, Malstrom K, Hampel FC Jr, et al; for Montelukast Spring Rhinitis Study Group. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32:1020–1028.
  5. Data available on request from Merck & Co., Inc., Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package 20603133(2)-SNG.
  6. Data available on request from Merck & Co., Inc., Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package 20506331(3)-SNG.
  7. Hadley JA, Kavuru MS, Anon JB, Pien LC. Rhinitis: pathogenesis. In: Diagnosis and Management of Rhinitis and Rhinosinusitis. 3rd Ed. Caddo, OK: Professional Communications Inc; 2005:21–26.
  8. Ledford DK, Lockey RF. Allergic rhinitis: understanding the process. J Respir Dis. 1998;19:576–584.
  9. Nouri-Aria KT, O'Brien F, Noble W, Jabcobson MR, Rajakulasingam K, Durham SR. Cytokine expression during allergen-induced late nasal responses: IL-4 and IL-5 mRNA is expressed early (at 6 h) predominantly by eosinophils. Clin Exp Allergy. 2000;30:1709–1716.
  10. Frieri M. Differentiating and treating allergic rhinitis. Intern Med. 1998;19:44–48.
  11. Naclerio RM. Allergic rhinitis. N Engl J Med. 1991;325:860–869.
  12. Pipkorn U, Karlsson G, Enerback L. The cellular response of the human allergic mucosa to natural allergen exposure. J Allergy Clin Immunol. 1988;82:1046–1054.
  13. Volovitz B, Osur SL, Berstein JM, Ogra PL. Leukotriene C4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. J Allergy Clin Immunol. 1988;82:414–418.

SINGULAIR is indicated for relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and children aged 2 years and older and perennial allergic rhinitis in adults and children aged 6 months and older).

Important Information

In clinical trials, SINGULAIR was generally well tolerated, with a safety profile similar to that of placebo. Adverse events varied by age. The most commonly reported adverse events, occurring at a frequency of >1% and at an incidence greater than placebo, regardless of causality assessment, were sinusitis, upper respiratory infection, sinus headache, cough, epistaxis, headache, otitis media, pharyngitis, and increased ALT.

SINGULAIR is contraindicated in patients with hypersensitivity to any component of this product.

Before prescribing SINGULAIR, please read the Prescribing Information.

20753522(1)-09/08-SNG

For general information and other services for physicians

Merck Services Merck OnCall

SINGULAIR, Merck OnCall, and MerckServices are registered trademarks of Merck & Co., Inc.